Step Pharma
Last verified 2026-05-08. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $102.5Mattributed |
|---|---|
| Latest round | grant, $2.7M, 2026-04-01attributed |
| Founded | 2014 |
| Headquarters | Saint-Genis-Pouilly, France |
| Industry | biotech |
| Stage | unknown |
| Website | step-pharma.com |
Step Pharma develops first-in-class CTPS1 inhibitors for cancer, led by oral candidate dencatistat for blood cancers and solid tumors. It targets patients with T-cell and B-cell malignancies and other cancers. Its selective CTPS1 inhibition is a novel mechanism distinct from existing therapies.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-04-01 | grant | $2.7M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Grant, $2.7M | attributed | eu-grant named as publisher. No document URL on file. |
| Total raised $102.5M | attributed | eu-grant named as publisher. No document URL on file. |
| Company existence | self-reported | step-pharma.com, read 2026-05-08 |
| Description | self-reported | step-pharma.com, read 2026-05-08 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.